ReviewJournal of endocrinological investigation2026
Epidemiological and socio-economic burden of MASH (previously known as NASH) in Europe: a systematic literature review.
Review in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsMetabolic dysfunction-associated steatohepatitis (MASH) in the past known as non-alcoholic steatohepatitis (NASH) is a chronic liver disease that poses significant epidemiological, clinical and socio-economic challenges. Given the limited availability of data on disease burden, this systematic literature review aimed to describe epidemiology, mortality, quality of Life (QoL) and socio-economic burden associated with NASH/MASH.
methodsA systematic literature review was carried out in PubMed (Medline) and Embase using the terms "NASH/MASH" and terms related to epidemiology, mortality, QoL and resource utilization and costs. The search covered publications from January 1, 2014, to January 16, 2024, and was restricted to articles published in English, Italian and Spanish. A two steps screening phase was performed, and relevant data were extracted from the included articles following a full-text assessment.
resultsAmong the retrieved studies, 25 included epidemiological data, 14 addressed mortality, 11 focused on QoL, and 9 focused on resource utilization and economic burden. Within the different populations assessed, the prevalence of NASH/MASH ranged from 18% to 68%. Diagnosis of NASH/MASH was associated with increased mortality, reduced QoL and higher use of healthcare resources. Advanced stages of disease were associated with further deterioration of QoL and increased use of healthcare facilities. Hospitalization is the main cost driver, followed by outpatients visit and therapies. Annual costs per patient varied geographically, from 4,994€ in Italy to 9,541€ in the UK, with advanced stages associated with significantly higher costs.
conclusionThe findings revealed that MASH poses a significant epidemiological, clinical and socio-economic burden on the NHS and society. The marked heterogeneity across available studies underscores the need for updated research adopting the current disease definition. Further evidence is required to better characterise disease burden across stages of severity and to inform the development and implementation of effective strategies for improved disease management.
Indexed as
Identifiers
42570203What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.